AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

Tekijä Zielinski, Christoph C, Pinto, Carmine
Julkaisussa ESMO Open (2016)

ESMO Open—Cancer Horizons and the future of oncology

Tekijä Zielinski, Christoph C
Julkaisussa ESMO Open (2016)

CSCO joins ESMO Open—Cancer Horizons

Tekijä Zielinski, Christoph C, Wu, Yi-Long
Julkaisussa ESMO Open (2016)

ESMO Open: news in breast cancer 2019

Tekijä Lambertini, Matteo
Julkaisussa ESMO Open (2020)

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

Tekijä Ohe, Yuichiro, Zielinski, Christoph
Julkaisussa ESMO Open (2017)

ESMO Open special series on new emerging targets in cancer immunotherapy

Tekijä Lambertini, Matteo
Julkaisussa ESMO Open (2020)

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

Tekijä Morgan, Gilberto, Preusser, Matthias, Zielinski, Christoph
Julkaisussa ESMO Open (2020)

One year of ESMO Open: Cancer Horizons—where are we going from here?

Tekijä Zielinski, Christoph
Julkaisussa ESMO Open (2017)

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Tekijä Preusser, Matthias
Julkaisussa ESMO Open (2019)

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

Tekijä Burke, Patrick W, Hoelzer, Dieter, Park, Jae H, Schmiegelow, Kjeld, Douer, Dan
Julkaisussa ESMO Open (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Tekijä Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Julkaisussa ESMO Open (2020)

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

Tekijä Awada, Ahmad, Gligorov, Joseph, Jerusalem, Guy, Preusser, Matthias, Singer, Christian, Zielinski, Christoph
Julkaisussa ESMO Open (2019)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Tekijä Lambertini, Matteo, Preusser, Matthias, Zielinski, Christoph C
Julkaisussa ESMO Open (2019)

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Tekijä Lamarca, A., Foster, L., Satyadas, T., Siriwardena, A., Valle, J.W.
Julkaisussa ESMO Open (2021)

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Tekijä Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
Julkaisussa ESMO Open (2021)

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Tekijä Shi, L., Xu, C., Ma, Y., Ou, Q., Wu, X., Lu, S., Shao, Y., Guo, R., Kong, J.
Julkaisussa ESMO Open (2021)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue...

Tekijä Lee, R.J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., Aung, T., Banfill, K., Baxter, M., Boyce, H., Brearton, G., Copson, E., Dickens, E., Eastlake, L., Gomes, F., Hague, C., Harrison, M., Horsley, L., Huddar, P., Hudson, Z., Khan, S., Khan, U.T., Maynard, A., McKenzie, H., Palmer, D., Robinson, T., Rowe, M., Thomas, A., Tweedy, J., Sheehan, R., Stockdale, A., Weaver, J., Williams, S., Wilson, C., Zhou, C., Dive, C., Cooksley, T., Palmieri, C., Freitas, A., Armstrong, A.C.
Julkaisussa ESMO Open (2021)

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO...

Tekijä Banna, G.L., Cortellini, A., Cortinovis, D.L., Tiseo, M., Aerts, J.G.J.V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., Berardi, R., Morabito, A., Genova, C., Mazzoni, F., Di Noia, V., Signorelli, D., Gelibter, A., Macerelli, M., Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Marco, R., Cantini, L., Nigro, O., D'Argento, E., Buti, S., Minuti, G., Landi, L., Guaitoli, G., Lo Russo, G., De Toma, A., Donisi, C., Friedlaender, A., De Giglio, A., Metro, G., Porzio, G., Ficorella, C., Addeo, A.
Julkaisussa ESMO Open (2021)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

Tekijä De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Caputo, R., Cianniello, D., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., Arpino, G.
Julkaisussa ESMO Open (2021)

In the literature: April 2017

Tekijä Cervantes, Andrés
Julkaisussa ESMO Open (2017)